PET Scan Proven Effective for Cardiac Amyloidosis

A new phase III study found that 124I-evuzamitide PET scans identify cardiac amyloidosis more accurately than existing methods.

Updated on Oct. 12, 2026 in Heart Disease

PET Scan Proven Effective for Cardiac Amyloidosis

Live Poll

Do you trust that new medical diagnostic technologies are quickly becoming available to your local doctors?

The phase III REVEAL study demonstrated that 124I-evuzamitide PET scans successfully detect cardiac amyloidosis with high sensitivity and specificity. Bayer now plans to submit the imaging agent for regulatory approval.

Why it matters

Current diagnostic tools like bone-avid tracers frequently produce false negatives during early disease stages. This new PET scan method offers a more precise alternative for identifying cardiac amyloidosis, potentially improving early intervention.

The REVEAL study of 170 participants, with a median age of 72, showed 124I-evuzamitide achieved a 93.5% sensitivity and 86.0% specificity. Results also confirmed a 94.1% negative predictive value and an 84.7% positive predictive value.

The players

Bayer

Bayer is a multinational pharmaceutical and biotechnology company that plans to seek regulatory approval for 124I-evuzamitide.

HFSA

The Heart Failure Society of America is an organization dedicated to improving the care of patients with heart failure through research and education.

The details

Participants in the study received 1 mCi of 124I-evuzamitide for imaging and were administered oral potassium iodide for 3 days to protect the thyroid. The scans successfully detected early ATTR amyloidosis at a higher rate than traditional bone scintigraphy, with no patients missed that were previously identified by scintigraphy.

The results were presented on October 12, 2026, at the HFSA annual meeting.

Health Landscape

This development represents a major step forward from the diagnostic limitations of bone scintigraphy for early-stage ATTR. By providing higher sensitivity, it addresses the historical challenge of false negatives in early amyloidosis detection.

If approved, this diagnostic tool could offer patients a more reliable way to detect cardiac amyloidosis early. This shift would allow clinicians to bypass the limitations of current scans, potentially leading to faster and more accurate treatment plans.

The takeaway

Advancements in PET imaging are narrowing the gap in early diagnosis for complex heart conditions. Patients should consult with their cardiologists about new diagnostic research if they are being evaluated for amyloidosis symptoms.